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Abstract 
Background: The private sector supplies anti-malarial treatment for large proportions of patients in sub-Saharan 
Africa. Following the large-scale piloting of the Affordable Medicines Facility-malaria (AMFm) from 2010 to 2011, a 
private sector co-payment mechanism (CPM) provided continuation of private sector subsidies for quality-assured 
artemisinin combination therapies (QAACT). This article analyses for the first time the extent to which improvements 
in private sector QAACT supply and distribution observed during the AMFm were maintained or intensified during 
continuation of the CPM through 2015 in Kenya, Madagascar, Nigeria, Tanzania and Uganda using repeat cross-sec-
tional outlet survey data.
Results: QAACT market share in all five countries increased during the AMFm period (p < 0.001). According to the 
data from the last ACTwatch survey round, in all study countries except Madagascar, AMFm levels of private sector 
QAACT availability were maintained or improved. In 2014/15, private sector QAACT availability was greater than 70% 
in Nigeria (84.3%), Kenya (70.5%), Tanzania (83.0%) and Uganda (77.1%), but only 11.2% in Madagascar. QAACT market 
share was maintained or improved post-AMFm in Nigeria, Tanzania and Uganda, but statistically significant declines 
were observed in Kenya and Madagascar. In 2014/5, QAACT market share was highest in Kenya and Uganda (48.2 and 
47.5%, respectively) followed by Tanzania (39.2%), Nigeria (35.0%), and Madagascar (7.0%). Four of the five countries 
experienced significant decreases in median QAACT price during the AMFm period. Private sector QAACT prices 
were maintained or further reduced in Tanzania, Nigeria and Uganda, but prices increased significantly in Kenya and 
Madagascar. SP prices were consistently lower than those of QAACT in the AMFm period, with the exception of Kenya 
and Tanzania in 2011, where they were equal. In 2014/5 QAACT remained two to three times more expensive than the 
most popular non-artemisinin therapy in all countries except Tanzania.
Conclusions: Results suggest that a private sector co-payment mechanism for QAACT implemented at national 
scale for 5 years was associated with positive and sustained improvements in QAACT availability, price and market 
share in Nigeria, Tanzania and Uganda, with more mixed results in Kenya, and few improvements in Madagascar. The 
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Background
The private sector is key to the provision of malaria treat-
ment in many countries in sub-Saharan Africa, constitut-
ing a substantial proportion of the overall market [1], and 
tending to reach the poorest segments of many societies 
[2]. However, in many cases, sub-Saharan African private 
sector anti-malarial markets have been characterized by a 
predominance of anti-malarial medicines that are banned 
or no longer recommended, including non-artemisinin 
therapies and artemisinin monotherapies [1]. Uptake of 
the World Health Organization’s recommended first-line 
treatment for uncomplicated malaria, artemisinin-based 
combination therapy (ACT) [3], has in the past been lim-
ited by a lack of consumer access [1, 4], and when available, 
high relative costs outside of the public sector [5, 6]. Inad-
equate access to prompt and effective treatment contin-
ues to contribute to malaria deaths in endemic countries 
of sub-Saharan Africa; of the 438,000 global deaths from 
malaria in 2015, 90% reportedly occurred in the region [7].
In order to increase utilization of the most effective 
treatments for malaria, the Affordable Medicines Facility-
malaria (AMFm) was established by the Global Fund to 
Fight AIDS, Tuberculosis and Malaria (the Global Fund, 
hereafter) in 2010 with the aim of increasing uptake of 
quality-assured ACT medicines (QAACT) and decreasing 
use of artemisinin monotherapies. The AMFm aimed to 
(1) increase affordability, (2) increase availability and (3) 
increase use of QAACT, and (4) to crowd out artemisinin 
monotherapies. The AMFm consisted of nine pilots in 
eight countries (Cambodia, Ghana, Kenya, Madagascar, 
Niger, Nigeria, Uganda, and Tanzania mainland and Zan-
zibar) (although Cambodia was not included in the inde-
pendent evaluation due to implementation delays). The 
AMFm aimed to achieve its four goals through negotiat-
ing QAACT price reductions from manufacturers, and 
subsidizing their prices through co-payment, adminis-
tered at the manufacturer level. Supporting interventions 
for the subsidy programme included behaviour change 
communications (BCC), the training of private sector 
vendors, and the introduction of recommended retail 
prices for QAACT. All Global Fund subsidised QAACT 
packaging carried a green leaf logo which was promoted 
in demand creation activities as an indication of quality 
and affordable anti-malarial treatment.
An independent evaluation of the AMFm in 2012 dem-
onstrated substantial increases in availability and market 
share, and large price decreases for QAACT in six out 
of eight pilots. The results of the AMFm evaluation have 
been described in detail elsewhere [8–10]. Briefly, the 
benchmark of a 20% point increase in QAACT availabil-
ity was met in five out of the eight pilots. The benchmark 
of a 10% point increase in QAACT market share was met 
in four pilots, with a further three having weak statistical 
evidence. Finally, the benchmark of QAACT prices fall-
ing below three times the price of the most popular non-
ACT anti-malarial in the country was met in five pilots. 
When applied to the private sector alone, the independ-
ent evaluation’s conclusions regarding the success metrics 
still hold. Positive market shifts were found to be largely 
due to changes in the private for-profit sectors in pilot 
countries [9]; indeed, the subsidy facility was described 
as a ‘game changer’ in the private for-profit sectors of all 
but two countries by the independent evaluators [8]. A 
systematic review of the literature examining the effects 
of anti-malarial subsidies likewise found subsidies to be 
successful in increasing availability and reducing costs of 
ACT. Furthermore, improved availability and affordabil-
ity tended to be equitable between rural and urban areas, 
and across income gradients [11]. The AMFm evaluation 
also found this to be the case in several pilots [8]. Fol-
lowing the AMFm period, the Global Fund continued a 
QAACT subsidy programme termed the private sector 
co-payment mechanism (CPM). The CPM has been in 
operation at national scale in six countries since the end 
of the AMFm pilot and the subsequent transition period 
in 2013. However, there is no published evidence to-date 
on the effectiveness of the CPM. This paper addresses 
that gap by examining post-pilot evidence in five coun-
tries: Nigeria, Kenya, Madagascar, Tanzania and Uganda.
Description of the private sector co‑payment mechanism
Following on the AMFm pilot phase from 2010 to 2011, 
the programme of subsidies and price negotiations con-
tinued in six countries: Ghana, Kenya, Madagascar, 
Nigeria, Tanzania and Uganda. Initial support for the 
subsidy provided by AMFm Phase 1 donors (i.e., Bill and 
Melinda Gates Foundation, UK Department for Interna-
tional Development [DFID], Government of Canada and 
subsidy mechanism as implemented over time across countries was not sufficient on its own to achieve optimal 
QAACT uptake. Supporting interventions to address continued availability and distribution of non-artemisinin thera-
pies, and to create demand for QAACT among providers and consumers need to be effectively implemented to real-
ize the full potential of this subsidy mechanism. Furthermore, there is need for comprehensive market assessments to 
identify contemporary market barriers to high coverage with both confirmatory testing and appropriate treatment.
Keywords: Artemisinin combination therapy, Private sector, Case management, Global Fund, Malaria treatment
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UNITAID) continued during a transition period, until 
implementation of a mechanism funded by the Global 
Fund called the CPM for ACT. The grant-funded CPM 
may now be included as part of a country’s malaria fund-
ing application to the Global Fund.
Figure 1 summarizes quantities of co-paid ACT deliv-
ered to the private sector during the AMFm period and 
the CPM through 2015 within the five countries included 
in this study (all CPM countries except Ghana), and refer-
ences the population size of each country [12] (Personal 
Communication, Global Fund Sourcing Department 
2016). Within each country, the peak for delivery of co-
paid doses occurred after the evaluated pilot period, 2015 
in Nigeria, or in 2012 or 2013 for the other four countries.
The CPM operated using the three key elements of the 
AMFm: price negotiations with manufacturers, ACT sub-
sidies at ‘factory gate’, and additional supporting interven-
tions. The CPM focuses exclusively on the private for-profit 
sector supply of QAACT given that the independent evalu-
ation showed that AMFm had greater impact on the sup-
ply of QAACT in the private than the public sector. Prior to 
the AMFm period, the Global Fund was a primary source 
of funding for QAACT within the public sector of pilot 
countries [9], and this funding support for the public sec-
tor continued post-AMFm outside of the CPM. The CPM 
therefore complemented Global Fund support to the public 
sector by providing a mechanism for improving access to 
QAACT in the private sector with the aim of reaching the 
large proportion of the population in participating coun-
tries seeking fever treatment in this sector.
The extent to which supporting interventions were 
implemented within each country post-AMFm varied 
greatly. Mass communication campaigns, private pro-
vider training, independent monitoring of retail price 
and availability, and policy and/or regulatory changes 
were implemented at various time points in the five 
countries examined here (Fig. 2) (Personal Communica-
tion, National Malaria Control Programmes).
The AMFm was characterized by a high degree of cen-
tralized management by a dedicated Global Fund Secre-
tariat. In the transition to the CPM, many aspects that 
had been centrally managed and controlled under the 
Fig. 1 Quantity of co-paid ACT delivered to private sector first-line buyers, 2010–2015
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AMFm were devolved to national level under the respon-
sibility of the Global Fund Principal Recipient (PR) with 
guidance from a national co-payment task force. Key 
changes in the mechanism that occurred in the transition 
from AMFm to CPM are detailed in Table 1.
With devolution of certain components of the CPM 
to country level, there was more room for variation 
between countries in subsidy levels, and greater flexibil-
ity to respond to local anti-malarial market conditions. 
Table 2 outlines changes in subsidy levels that occurred 
within each country post-pilot through 2015. Madagas-
car was the only AMFm country in this study to main-
tain the 95% subsidy for first-line buyers. Elsewhere, the 
subsidy level was reduced to as low as 70% in Kenya and 
Uganda.
The extent to which any of the successes identified 
in the independent evaluation of the AMFm have been 
maintained or improved upon with implementation of 
the CPM is unreported in the literature to-date. The aim 
of this paper is to analyse what happened to QAACT 
market share, availability and price in the private for-
profit sector during the period following the AMFm. 
Specifically, we use ACTwatch outlet survey data to 
examine to what extent the changes observed during the 
2010–2011 evaluated period of the pilot were maintained 
with implementation of the CPM through 2014/15 in 
five countries, and where they were maintained, whether 
there have been significant improvements in those 
indicators.
Methods
ACTwatch was launched in 2008 by Population Services 
International (PSI) in collaboration with the London 
School of Hygiene and Tropical Medicine with support 
from the Bill and Melinda Gates Foundation. The goal 
of the project was to generate timely, relevant and high 
quality evidence about anti-malarial markets for policy 
makers, donors and implementing organisations. As of 
2016, ACTwatch had gathered data from a total of 12 
malaria endemic countries in sub-Saharan Africa and the 
Greater Mekong Sub-region. This paper presents data 
from outlet surveys in five sub-Saharan countries that 
took part in the AMFm pilot. It excludes data from other 
countries that were not part of the AMFm pilot. Detailed 
ACTwatch project and methodological information have 
been published elsewhere [13, 14].
Country Supporng intervenon type
2012 2013 2014 2015
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Nigeria
Communicaons
Training
Monitoring
Regulaon
Kenya
Communicaons
Training
Monitoring
Regulaon
Tanzania
Communicaons
Training
Monitoring
Regulaon
Uganda
Communicaons
Training
Monitoring
Regulaon
Madagascar
Communicaons
Training
Monitoring
Regulaon
Communicaons Mass communicaon campaigns to increase public awareness about the co-payment and important aributes of co-paid products.
Training Private sector provider training 
Monitoring Periodic (e.g. quarterly) monitoring of retail price and availability implemented by an independent enty in order to guide management decisions on implementaon of the PSCM
Regulaon Policy and/or regulatory changes at the country level (e.g. banning sales and importaon of artemisinin monotherapies, granng waivers for import dues and taxes)
Fig. 2 Timeline of CPM supporting interventions implementation
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Design and sampling
ACTwatch outlet surveys are nationally-representative 
cross-sectional quantitative surveys conducted among a 
sample of outlets stocking anti-malarial medicines and 
diagnostics. Surveys were repeated over time to inform, 
monitor and evaluate policies and strategies designed 
to improve access and use of malaria diagnostics and 
first-line treatments. A detailed description of the ACT-
watch outlet survey methods is available elsewhere [13]. 
Briefly, all categories of outlets with the potential to stock 
anti-malarials in both the public and private sector were 
included in the study. In the public sector, this included 
government and non-government not-for-profit health 
facilities (hospitals, centres, clinics and posts) and com-
munity health workers. Outlets sampled in the private 
sector included private for-profit health facilities (hospi-
tals, centres and clinics), pharmacies, drug stores (regis-
tered/regulated and unregistered/unregulated), general 
retailers selling fast-moving consumer goods, and itiner-
ant drug vendors (mobile vendors without a fixed service 
delivery point).
Lists of all potentially eligible outlets were not routinely 
available and therefore a cluster sampling approach with 
an outlet census was used to identify outlets for inclu-
sion. Clusters were administrative units ideally with 
a typical size of 10,000–15,000 inhabitants, and were 
selected using probability proportional to population size 
sampling. Within each selected cluster all outlet types 
with the potential to provide anti-malarials to consumers 
were screened, with anti-malarial audits completed in all 
outlets found to have one or more anti-malarials in stock 
the day of the survey.
Boundaries for the outlet census were typically 
extended to larger administrative units for the census of 
public health facilities and pharmacies, in order to over-
sample these relatively uncommon but important outlet 
types.
Each study was stratified to deliver estimates for rele-
vant research domains. All countries had urban and rural 
stratification, with the exception of Nigeria in 2009, 2013 
and 2015, for which six geopolitical zones were used as 
research domains. Each study round was powered to 
detect a minimum of a 20% point change in QAACT 
availability among anti-malarial stocking outlets between 
each round and within each domain at the 5% signifi-
cance level with 80% power. The number of study clusters 
was calculated for each research domain based on the 
required number of anti-malarial stocking outlets and 
assumptions about the number of anti-malarial stocking 
outlets per cluster. Sample size requirements for follow-
up surveys were calculated using information from pre-
vious survey rounds including anti-malarial and QAACT 
availability, outlet density per cluster, and design effect.
Data collection periods varied by country and over 
time but were typically during the peak malaria transmis-
sion season for each country and lasted between 6 weeks 
and 2 months. Efforts were made to ensure surveys were 
implemented over similar time points across the survey 
rounds.
Training and fieldwork
Interviewer training consisted of standardized classroom 
presentations and exercises as well as a field exercise. 
Exams administered during training were used to select 
data collectors, supervisors, and quality-controllers, 
who received additional training. Data collection teams 
were provided with a list of selected clusters and official 
maps that illustrated administrative boundaries. In each 
selected cluster, fieldworkers conducted a full enumera-
tion of all outlets that had the potential to provide anti-
malarials. This included enumeration of outlets with a 
physical location, as well as identification of community 
health workers and itinerant drug vendors using local 
informants. The primary provider/owner of each out-
let was invited to participate in the study and screening 
questions were administered to assess anti-malarial avail-
ability. Interviews were conducted in the local language 
using questionnaires that were translated from English to 
the local language and back to English to confirm trans-
lations. All surveys were paper-based with the excep-
tion of Madagascar 2015 and Uganda 2015, where data 
were collected using Android phones and forms created 
using DroidDB (©SYWARE, Inc., Cambridge, MA, USA). 
Quality control measures implemented during data col-
lection included questionnaire review by supervisors 
and interview verification visits conducted by quality 
controllers to between 10 and 20% of all outlets. Any dis-
crepancies that were found were resolved. Double data 
entry was conducted using Microsoft Access (Microsoft 
Table 2 Subsidy levels for the CPM. Source: Personal Com-
munication, The Global Fund, 24/08/2016
Nigeria Early to mid-2013: changed to 85% subsidy for all pack 
sizes
Kenya Early to mid-2013: changed to 70% subsidy for all pack 
sizes
Tanzania Early 2014: changed to 80% adult and 90% paediatric 
subsidy levels
Early 2015: changed to 75% adult and 85% paediatric 
subsidy levels.
Uganda Early 2014: changed to 50% adult and 70% paediatric 
subsidy levels
Mid- 2015: changed to 70% subsidy for all pack sizes
Madagascar Maintained the 95% subsidy for all pack sizes
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Corporation, Redmond, WA, USA) with built-in range 
and consistency checks.
Information collected on anti‑malarials
The outlet survey questionnaire included an audit of all 
available anti-malarial medicines. Providers were asked 
to show the interviewer all anti-malarial medicines cur-
rently available. A product audit sheet captured informa-
tion for each unique anti-malarial product in the outlet, 
including formulation, brand name, active ingredients 
and strengths, package size, manufacturer and country 
of manufacture. Providers were asked to report the retail 
price for each medicine as well as the amount distributed 
to individual consumers (as opposed to wholesale pur-
chasers) in the last week.
Data analysis
Data were analysed across survey rounds using Stata 
(StataCorp College Station, TX) and R (©The R Founda-
tion, Vienna, Austria). Standard indicators were con-
structed according to definitions applied across the 
ACTwatch project and have been described in detail else-
where [1, 14]. Briefly, anti-malarials identified during the 
outlet drug audit were classified according to information 
on drug formulation, active ingredients and strengths 
as non-artemisinin therapies, artemisinin monothera-
pies and ACT. Non-artemisinin therapies were classified 
as sulfadoxine pyrimethamine (SP) or other non-arte-
misinin therapies. Although no longer indicated for 
malaria case management, SP is still purchased for case 
management and recommended in all study countries for 
intermittent preventive therapy of malaria during preg-
nancy (IPTp). Artemisinin monotherapies were further 
classified as oral and non-oral, the latter including medi-
cines recommended for the first-line treatment of severe 
malaria. ACT were classified as QAACT or non-QAACT. 
QAACT were ACT granted World Health Organiza-
tion (WHO) prequalification, ACT in compliance with 
the Global Fund Quality Assurance Policy, on the Global 
Fund list of approved pharmaceutical products for pro-
curement, or ACT granted regulatory approval by the 
European Medicines Agency (EMA). Classification was 
completed by matching product audit information (for-
mulation, active ingredients, strengths, manufacturer, 
country of manufacture and package size) to the most 
recent lists of approved medicines available from the 
WHO, Global Fund, and EMA for each survey round.
Anti-malarial market composition was defined as the 
percentage breakdown of anti-malarial outlets by type, 
with anti-malarial outlets defined as all those with anti-
malarials in stock on the day of the survey. QAACT 
availability is presented out of those outlets that had 
anti-malarials in stock. Significant differences in QAACT 
availability levels between years in each country were 
estimated using logistic regression, with a binary depend-
ent variable for availability of QAACT at the outlet level, 
and a dummy independent variable for year.
To calculate market share, anti-malarial sales were 
standardized to allow meaningful comparisons between 
anti-malarials with different treatment courses and dif-
ferent formulations. The adult equivalent treatment dose 
(AETD) was defined as the amount of active ingredient 
required to treat an adult weighing 60  kg according to 
WHO treatment guidelines [3]. Provider reports on the 
amount of the drug sold or distributed during the week 
preceding the survey were used to calculate volumes in 
AETDs according to type of anti-malarial. Measures of 
volume included all dosage forms to provide a complete 
assessment of anti-malarial market share. The statistical 
significance of differences in QAACT market share was 
estimated using Stata’s ratio command, and the post-esti-
mation ‘lincom’ (linear combination) command.
Median private sector price per AETD was calculated 
for QAACT and for the most popular non-artemisinin 
therapy in the most recent round, SP. The interquar-
tile range (IQR) is presented as a measure of dispersion. 
Price data were collected in local currencies and deflated 
to 2009 US dollar prices using national consumer price 
indices and published exchange rates for the period of 
data collection. While all QAACT are by definition tablet 
formulations, SP may be available in other formulations 
including syrups and injections. Price measures included 
tablet anti-malarials only, given differences in unit costs 
for tablet and non-tablet formulations. Statistical sig-
nificance for year on year differences in median price in 
each country was estimated in R, using the Mann–Whit-
ney–Wilcoxon test. Because this test provides a measure 
of relative rank, rather than strictly testing for the differ-
ence between two medians, it is possible that significant 
differences will be identified when there is no difference 
between the medians themselves [15]. This therefore 
would represent a difference in the price distribution 
between 2 years, rather than directly a difference between 
two medians.
Sampling weights were calculated as the inverse of the 
probability of cluster selection. All point estimates were 
weighted using survey settings and all standard errors 
calculated taking account of the clustered and stratified 
sampling strategy with the relevant suite of survey com-
mands in each statistical package.
Results
A total of 139,738 outlets were screened to assess avail-
ability of anti-malarial medicines across the five coun-
tries and 18 survey rounds between 2009 and 2015. 
An audit of all available anti-malarials was completed 
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in 34,441 outlets. In total, 242,541 anti-malarial drugs 
were audited. Table 3 shows a detailed breakdown of the 
screening and audit results for each survey round.
The private sector constituted the majority of service 
delivery points for malaria treatment provision in four 
out of the five countries. Figure  3 shows that in terms 
of absolute number of places where anti-malarial medi-
cines were available, most were categorized as private 
for-profit outlets. Only Madagascar had a majority of 
outlets in the public/not-for-profit sector, where com-
munity health workers represented 51.7% of all outlets, 
and a large majority, therefore, of all public sector outlets. 
The private sector nevertheless represented a substan-
tial proportion of the anti-malarial market in Madagas-
car. In the other four countries, drug stores tended to be 
the most numerous outlet type among all those provid-
ing malaria treatment. In Nigeria and Tanzania, drug 
stores accounted for more than half of all anti-malarial 
service delivery points (76.0 and 70.2%, respectively). 
Private for-profit health facilities and pharmacies tended 
to be less numerous, although they accounted for a sub-
stantial proportion of all anti-malarial stocking outlets 
in Kenya (21.4 and 11.8%, respectively). The extent to 
which general retailers were part of the anti-malarial 
market varied, from Uganda where general retailers were 
not involved in anti-malarial distribution, to Kenya and 
Madagascar where about one in five anti-malarial stock-
ing outlets were general retail shops (19.8% in Kenya; 
20.9% in Madagascar). In Kenya, this means that nearly 
one in four (23.0%) private sector outlets providing anti-
malarials were general retailers, and in Madagascar, over 
half (56.0%) of anti-malarial stocking private sector out-
lets were general retail outlets. Itinerant drug vendors 
with anti-malarials in stock were uncommon across all 
countries, although found in both Madagascar and Nige-
ria (2.5 and 1.1% of all outlets stocking anti-malarials, 
respectively).
Private sector QAACT availability
Figure  4 summarizes the availability of QAACT among 
anti-malarial stocking private sector outlets pre- 
(2009/2010) and post-(2011) AMFm, and subsequently 
during implementation of the CPM. QAACT availability 
in the most recent survey round was greater than 70% 
in Nigeria, Kenya, Tanzania and Uganda. The highest 
level was found in Nigeria, where QAACT availability 
exceeded 80% in 2015 (84.3%). Madagascar had a sub-
stantially lower level of QAACT availability, at 11.2% in 
2015.
Significant increases were found in availability between 
pairs of consecutive survey rounds in all countries for 
at least one post-2011 time period. In Nigeria, QAACT 
Table 3 Results of the outlet census and anti-malarial audit by country and survey year
Country Year Screened (N) Outlets the met screen‑
ing criteria
Anti‑malarial audit 
complete (N)
Anti‑malarials 
audited (N)
QA ACT audited (N)
West & Central Africa
 Nigeria 2009 5456 2210 2113 20,841 1192
2011 7938 1567 1486 13,391 2119
2013 5148 1828 1714 14,358 4799
2015 13,483 3624 3473 33,532 9581
East Africa
 Kenya 2010 13,897 2625 1888 8376 2052
2011 11,383 2112 1854 9544 3669
2014 12,676 2477 2133 9899 3234
 Tanzania 2010 3120 710 624 5544 416
2011 3702 799 787 9701 2045
2014 4724 2160 2129 17,307 4905
 Uganda 2010 11,153 2590 2410 14,427 2893
2011 16,207 3285 3138 20,283 5495
2013 7932 3504 3307 19,777 7182
2015 9438 4780 4328 26,640 7380
Southern Africa
 Madagascar 2010 6769 2642 2414 5579 1790
2011 10,046 2854 2360 7234 3233
2013 10,149 2021 1756 6101 3851
2015  13,481 1361  1040  3170 1501
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availability rose by 21% points in the period 2011–2013 
(p  <  0.001) and then by a further 10% points through 
2015 (p  <  0.05). Kenya and Tanzania also experienced 
statistically significant increases in availability of 10% 
points (p < 0.05) and 16% points (p < 0.001) respectively 
between 2011 and 2014. In Uganda, a significant increase 
in availability was observed between 2011 and 2013, and 
this level of availability (over 75%) was also maintained in 
the most recent survey round (no significant difference). 
In Madagascar, there was no significant rise in availability 
during AMFm, however QAACT availability increased 
by 19% points between 2011 and 2013 (p  <  0.001), but 
decreased significantly to near pre-AMFm levels in 2015 
(p < 0.001).
Private sector anti‑malarial market share
Figure 5 summarizes QAACT anti-malarial market share 
in the private sector pre- (2009/2010) and post- (2011) 
AMFm, and subsequently during implementation of the 
CPM. Market share is also shown for non-QAACT, non-
artemisinin therapies and artemisinin monotherapies. 
The share of private for-profit anti-malarial distribution 
accounted for by QAACT varied across countries, but 
was less than 50% in all countries. In the most recent sur-
vey round, it was highest in Kenya and Uganda (at 48.2 
and 47.5%, respectively), followed by Tanzania (39.2%) 
and Nigeria (35.0%). QAACT market share was lowest in 
Madagascar (7.0%) in 2015.
QAACT market share in all five countries increased 
during the AMFm period (p  <  0.001). In both Tanza-
nia and Uganda, QAACT market share increases were 
maintained (no significant change compared with post-
2011 levels), while in Nigeria there were further statis-
tically significant increases in QAACT market share 
between survey rounds (p  <  0.001 between 2011-2013 
and 2013-2015). Kenya saw a statistically significant 
decrease in QAACT market share between 2011 and 
2014 (p < 0.001). However, ACT market share in Kenya 
remained similar between 2011 and 2014 with non-
QAACT appearing to have displaced QAACT during 
this period. In Madagascar, initial post-AMFm gains in 
QAACT market share (p  <  0.05) had been eliminated 
by the most recent survey round, with large, significant 
declines (p < 0.001), returning to pre-AMFm levels.
Data within each type of private sector outlet show 
that QAACT market share improvements in the case of 
Public health facility
Community health workers
Private not-for-profit facility
Private for-profit facility
Pharmacy
Unregistered pharmacy
General retailer
Itinerant vendor
Nigeria 2015, N=3470
Tanzania 2014, N=535 Uganda 2015, N=2339 Madagascar 2015, N=842
Kenya 2014, N=1501
Fig. 3 Anti-malarial market composition by country for the most recent survey round
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Nigeria, Tanzania and Uganda, and declines in Kenya and 
Madagascar were not necessarily uniform across all out-
let types (Additional file 1).
Non-artemisinin therapies accounted for about one-
third of all anti-malarials distributed in the private sector 
during the most recent survey rounds in Kenya (30.2%) 
and Uganda (32.0%), almost half in Nigeria (48.8%) and 
over half in Tanzania (55.7%) and Madagascar (93.6%). 
The most common type of non-artemisinin therapy dis-
tributed in each country’s private sector was SP.
Oral artemisinin monotherapy was found consistently 
only in Nigeria’s private sector. Market share for oral 
artemisinin monotherapy in Nigeria fell significantly 
between 2011 and 2013 (p < 0.001), and did not increase 
significantly between 2013 and 2015. Nevertheless, oral 
artemisinin monotherapy accounted for 2.5% of market 
share in the most recent survey round.
Private sector price
Four of the five countries experienced significant 
decreases in median QAACT price during the AMFm 
period (to 2011). Post-AMFm pilot, these prices were 
maintained in Nigeria and Uganda to 2013 and then 
underwent a decline in both countries between 2013 
and 2015 (p  <  0.001). In Tanzania, the median price of 
QAACT remained the same between 2011 and 2014, 
however the distribution of prices, as illustrated in the 
upwards shift in IQR, resulted in a statistically significant 
test results for price trend (p  <  0.001). Price increased 
significantly in Kenya between 2011 and 2014 (p < 0.001), 
although remained consistently below pre-AMFm lev-
els. The price of QAACT in Madagascar rose during the 
AMFm period, and despite small but significant price 
declines between 2011 and 2013 (p  <  0.001), QAACT 
price increased between 2013 and 2015 (p  <  0.001) 
(Fig.  6). This rise was likely due to large price increases 
per AETD of artemether-lumefantrine (AL) in Madagas-
car in that period, as artesunate-amodiaquine (ASAQ) 
price remained stable.
SP prices were consistently lower than those of 
QAACT in both the AMFm and CPM periods, with the 
exception of Kenya and Tanzania in 2011, where they 
were equal. Price differences between SP and QAACT 
have narrowed considerably since 2009/2010. In the most 
recent survey round, QAACT and SP prices were most 
similar in Tanzania (in 2014), when QAACT remained 
1.3 times more expensive than SP. In all other countries, 
QAACT were two to three times more expensive than SP 
during the most recent survey round (Nigeria, 3.4; Kenya, 
2.6; Uganda, 3.4; Madagascar, 2.8) (Additional file 2).
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Price data were disaggregated by package size for the 
most common QAACT type in each country (ASAQ in 
Madagascar, AL in the other four countries) (Figs.  7, 8, 
9, 10). Post-AMFm falls in prices seen at aggregate level 
in Uganda and Nigeria clearly occurred across all pack-
age sizes. Post-AMFm increases in price in Kenya and 
Tanzania were observed for larger pack sizes, but not for 
AL 6-tablet pack in both countries, and the AL 12-tablet 
pack in Tanzania.
Discussion
This paper examined whether the successes of the 
AMFm in improving availability, market share and price 
of QAACT between 2010 and 2011 [9] were maintained 
or improved upon with continuation of a private sec-
tor co-payment mechanism administered by the Global 
Fund through 2014/15. The results are particularly sig-
nificant given the importance of the private sector in 
distributing anti-malarial drugs in these countries [1, 
4]. While encouraging, findings also highlight a need for 
further improvements in QAACT uptake in the private 
sector.
The improvements in anti-malarial markets observed in 
this study occurred in the context of an evolution in the 
copayment mechanism, from highly centralized manage-
ment under the controlled conditions of the time-limited 
AMFm pilot to decentralization of management and over-
sight to the national level in the CPM period. Each country 
set new subsidy levels, most often reducing the subsidy for 
first-line buyers, with the exception of Madagascar where 
the high subsidy level under AMFm was maintained. 
Supporting interventions were largely not systematically 
implemented across countries during the CPM period, 
with the exception of reported mass communications 
regarding the subsidy in Kenya. Implementation strength 
of supporting interventions was not measured. The num-
ber of co-paid ACT delivered to the private sector peaked 
after the period covered by the independent evaluation of 
AMFm in each country, indicating that demand and suc-
cessful resupply for first-line buyers continued under the 
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decentralized CPM model. These findings demonstrate 
operational effectiveness under sustained implementation 
outside of a tightly controlled pilot.
Post‑AMFm anti‑malarial market improvements
In the post-AMFm period, there were statistically sig-
nificant increases in private sector QAACT availability 
in Kenya, Madagascar, Nigeria, Tanzania and Uganda, 
but with a subsequent fall in the case of Madagascar. 
Furthermore, the vast majority of private sector outlets 
with anti-malarials in stock had QAACT in stock dur-
ing each survey round in all countries except Madagas-
car. The majority of people seeking malaria treatment 
in these countries do so in the private sector, and these 
results indicate that throughout the CPM period, they 
were likely to find QAACT in these private outlets, 
whereas before AMFm implementation this was not the 
case. Furthermore, post-AMFm QAACT market share in 
the private sector was maintained or further increased in 
Nigeria, Tanzania and Uganda.
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Persistent challenges to increased QAACT uptake
Despite these broadly positive results for availability and 
market share, there was evidence of a persistent gap in 
the uptake of QAACT after 4–5 years of a private sector 
copayment mechanism (2010–2014/15). While it should 
be recognised that implementation varied over time and 
across countries, and that funding and subsidy levels fell 
after the initial pilot period, it was notable that QAACT 
market share in the private sector remained at less than 
50% in each country. Non-artemisinin therapies, par-
ticularly SP, accounted for one-third to one-half of all 
anti-malarials distributed in Kenya, Nigeria, Tanzania 
and Uganda, and over 90% of anti-malarials distrib-
uted in Madagascar. Non-artemisinin therapies should 
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continue to account for a small portion of anti-malarial 
market share in all of these countries because SP is rec-
ommended for IPTp [3]. However, persistent substantial 
SP market share is cause for concern. Continued uses of 
SP likely include management of fever/malaria in people 
of all ages given the widespread availability of products 
with packaging and patient instructions for uncompli-
cated malaria.
The continuing sub-optimal QAACT market share, 
despite high availability, highlights the need for expan-
sion of supporting interventions to promote QAACT 
uptake. Persistent distribution of non-artemisinin thera-
pies despite availability of ACT has been documented 
in a number of countries within public and private sec-
tors and well before the AMFm pilot [16, 17]. Provider 
behaviour is one contributing factor to low ACT demand 
and use, and may reflect low levels of provider awareness 
about recommended first-line treatments and/or beliefs 
and preferences for non-first-line medicines [18–20]. 
Within the context of the AMFm, there is some evidence 
to suggest that communications campaigns implemented 
as part of the AMFm pilot may have been effective in 
increasing private provider knowledge regarding the 
first-line treatment [21]. However, awareness of official 
guidance is unlikely sufficient to drive ACT uptake alone 
and strategies are needed to influence not only provider 
knowledge but also provider preferences [22]. There is 
some evidence to suggest that trainings for providers 
in the informal private sector may have benefits [23]. 
Trainings targeting private providers were reportedly 
implemented as part of the CPM in Kenya and Nigeria, 
although evidence about implementation strength and 
effectiveness of these trainings is not available. There is 
need for additional evidence about private provider pref-
erences and practices to inform appropriate strategies to 
facilitate changes in stocking and dispensing behaviours 
in the context of mechanisms such as the CPM.
Low QAACT uptake is also influenced by consumer 
demand [20]. There is a gap in the contemporary evi-
dence base for information on factors influencing con-
sumer treatment-seeking behaviour. While a number 
of studies concerning patient treatment-seeking behav-
iour were conducted and summarized in key reviews 
in the 1990s and early 2000s [24, 25], there is need for 
updated evidence, particularly in the context of large-
scale investments and strategies to improve malaria case 
management in public and private sectors. The primary 
supporting intervention targeting consumers under the 
AMFm and CPM was mass media communications cam-
paigns with a focus on promoting ACT with the green 
leaf logo and in some instances, the recommended retail 
price. These were implemented to varying degrees across 
countries, however evidence on implementation strength 
and effectiveness vis-à-vis QAACT uptake is not avail-
able. Mass media communications campaigns have been 
shown to play an important role in a range of health 
interventions, particularly when part of a wider set of 
activities [26]. Although behaviour change communica-
tion has been a critical component of malaria strategies, 
most programs have not been rigorously evaluated. Evi-
dence is limited on effectiveness of various approaches 
and materials as well as on the overall effectiveness of 
communications for behaviour change in this context 
[27].
The relatively high cost of QAACT, despite reductions 
in price with AMFm and CPM interventions, may also 
be limiting QAACT update. SP remains less expensive 
than QAACT in all study countries, and QAACT were 
two to three times more expensive than SP during the 
most recent survey round in Kenya, Madagascar, Nigeria 
and Uganda. Reducing ACT retail price increases ACT 
use [6, 11], but results of this study suggest that retail 
prices achieved through the CPM model may not be low 
enough to achieve optimal uptake.
In addition to supporting interventions targeting pro-
vider and consumer behaviour, the policy and regulatory 
environment may influence the success of copayment 
mechanisms [24]. Strengthened policies and regulations 
may be needed to curtail the availability and distribution 
of artemisinin monotherapies for malaria case manage-
ment [28].
Finally, the requirements for such supporting interven-
tions are evolving in line with the goals of malaria case 
management in endemic country settings. WHO and 
national programme guidelines now place emphasis on 
confirmation of all suspected cases [29], meaning that 
there is need to re-evaluate the primary threats and spe-
cific barriers to case management in the private sector, 
and to develop locally tailored and global market-based 
approaches that will be cost-effective in ensuring not only 
use of appropriate and effective malaria treatments but 
also appropriate diagnosis.
Market deteriorations
In contrast to the generally positive trends in key indica-
tors in Nigeria, Tanzania and Uganda, results were mixed 
in Kenya and highly unfavourable in Madagascar. While 
QAACT availability in Kenya increased post-AMFm to 
just over 70%, market share significantly declined to less 
than 50%  coinciding with a drop in subsidy level from 
95% to 70%. At the same time, market share for non-
QAACT increased such that one in five anti-malarials 
distributed in Kenya in 2014 were non-QAACT, indicat-
ing that QAACT were to some extent displaced by non-
QAACT between 2011 and 2014 [30]. This is concerning 
given potential threats to patient health and malaria 
Page 16 of 18ACTwatch Group et al. Malar J  (2017) 16:173 
parasite clearance associated with using sub-standard 
medicines [31–35]. What appears to be a rising demand 
for and use of non-QAACT is particularly surprising 
given that Kenya reported implementing mass commu-
nications during the AMFm and continuing throughout 
CPM implementation. However, the reach and consist-
ency of these communications has not been formally 
assessed and effectiveness has not been established. It is 
also interesting to consider if a more gradual reduction in 
subsidy level over time might have preserved some of the 
QAACT market share in Kenya despite the retail price 
increase that would be expected following a reduction 
in subsidy level. Evidence is needed to inform additional 
strategies to generate and sustain demand for quality-
assured products.
In Madagascar, the AMFm yielded no significant 
improvements in private sector QAACT availability and 
significant but minimal improvements in private sector 
QAACT market share. Post-AMFm, QAACT market 
share and price increased to moderate levels between 
2011 and 2013, but then declined to pre-AMFm levels by 
2015. The CPM in Madagascar was halted between 2014 
and late 2015 following an investigation by the Global 
Fund’s Office of the Inspector General, resulting in very 
few co-paid ACT being delivered before the end of 2015, 
with only one round of co-payments held at the end of 
that year. The country’s 2009–2014 political crisis also 
had limiting effects on the extent of external donors’ sup-
port for health programmes in the public sector, with 
health commodity stock-outs and overall weak national 
health infrastructure and commodity management sys-
tems continuing to pose challenges [36]. Furthermore, 
an interruption to major Global Fund-funded activities 
during this period resulted in widespread ACT stock-
outs nationally. Further to these supply chain and health 
system problems, the supporting interventions relating 
to the CPM had not started as of the final survey round 
reported here (in 2015) (Personal Communication, The 
Global Fund). The relatively poor results in Madagascar 
can therefore perhaps be better understood as a reflec-
tion of poor implementation, rather than the failure of a 
well-implemented programme.
Limitations
This study has several limitations. First, the complex 
nature of the CPM, operating at national level in several 
countries with heterogeneous anti-malarial distribution 
chains and markets has meant that there were no good 
controls at sub-national or national level to use as com-
parators in this analysis. The degree to which we could 
make any kind of causal claims as to the effect of the 
CPM is therefore limited. Nevertheless, seen in the con-
text of the results of the AMFm independent evaluation, 
the evidence presented here from the post-pilot period 
is suggestive of continued effects of ‘factory gate’ subsi-
dies on the QAACT markets in the countries where the 
mechanism was active. Furthermore, a systematic review 
of the literature examining the effects of subsidies on key 
ACT indicators suggested that in smaller-scale RCTs, 
there was strong causal evidence that these subsidies 
could be successful in reducing ACT prices and increas-
ing their availability and market share in a range of set-
tings [37]; this reinforces the findings presented here.
A further limitation is our reliance on self-report survey 
data. In each country’s outlet surveys, while anti-malarial 
audits were carried out by researchers, still depended on 
prices and sales volumes reported by the outlet supervi-
sor. These responses were open to positive response bias. 
Differential levels of response bias for SP versus QAACT 
would not, however, necessarily be expected. It is possi-
ble though that there may be differential levels of response 
bias between survey rounds, as the emphasis placed on 
recommended retail price (RRPs) may have varied over 
time. As our focus has been on price difference between 
these two anti-malarials, rather than their absolute lev-
els, the effect of this potential bias should be limited here. 
Using price per AETD permits price comparisons over 
time, and between types of anti-malarial drugs, but we 
acknowledge that this measure is less useful in under-
standing what consumers typically pay for treatment, as 
this varies according to various factors such as pack size.
Conclusions
Improving the case management of malaria in the private 
sector is critical to improving coverage of appropriate 
malaria case management in many endemic countries. 
The results presented in this paper demonstrate that 
a private sector co-payment mechanism for QAACT, 
implemented at national scale for 5 years was associated 
with positive and sustained improvements in QAACT 
availability, price and market share in three out of five 
countries. These included the large West African coun-
try of Nigeria, with one of the highest malaria burdens in 
the world, as well as the East African countries of Uganda 
and Tanzania. Furthermore, substantial improvements 
in QAACT availability, price and market share observed 
during the AMFm period continued in these three coun-
tries as they transitioned to the CPM, characterized by 
decentralized management and national oversight of 
implementation. Mixed results were observed in Kenya, 
where post-AMFm QAACT market share was not main-
tained and QAACT appeared to have been displaced in 
part by non-QAACT following a reduction in the sub-
sidy level while the quantity of co-paid QAACT deliv-
ered remained nearly constant. It is worth noting though 
that the QAACT market share remained well above 
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pre-AMFm levels. In Madagascar, a number of contextual 
factors appear to have contributed to a lack of sustained 
market improvements under both the AMFm and CPM, 
including halted implementation of the programme. 
Results from this study suggest that a co-payment mech-
anism for QAACT targeting the private sector can be an 
effective and feasible strategy to improve availability and 
use of appropriate malaria treatment in malaria-endemic 
countries that have a substantial private sector mar-
ket. However, results also demonstrate that this subsidy 
mechanism was not sufficient alone to drive QAACT 
uptake to 100%. Supporting interventions to address 
availability and distribution of non-artemisinin therapies 
and to create demand for QAACT among providers and 
consumers may be needed to realize the full potential of 
this type of subsidy mechanism. Furthermore, there is 
need for comprehensive market assessments in malaria 
endemic countries to identify contemporary market bar-
riers to high coverage with not only appropriate malaria 
treatment but also confirmatory testing of all suspected 
cases.
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